This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EXEL or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 36.54% Upside in Exelixis (EXEL): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 36.5% upside potential for Exelixis (EXEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why
by Zacks Equity Research
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
Exelixis (EXEL) Down 7.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: PTGX Gains on Study Data, BMRN Faces Setback & More
by Zacks Equity Research
Pipeline and regulatory updates from Protagonist (PTGX) and BioMarin (BMRN) are the key highlights from the biotech sector during the past week.
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
by Zacks Equity Research
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
by Zacks Equity Research
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
by Zacks Equity Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
by Zacks Equity Research
Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.
Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 24% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
Are Investors Undervaluing Exelixis (EXEL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.